Learn More
Context: Ibrutinib, a first-in-class, once-daily oral, covalent inhibitor of Bruton's tyrosine kinase, demonstrated single-agent activity and an acceptable safety profile in a phase II relapsed/refractory (R/R) CLL/SLL study (Byrd et al. NEJM 2013). Ibrutinib is FDA approved for CLL patients who have received ≥1 prior therapy, and for patients with del(17p)(More)
New thalidomide derivatives CC-5013 and CC-4047 (immunomodulatory drugs, IMiD) are up to 10,000 times more potent than Thalidomide. The biological effects of IMiDs are presumed to be mediated by (a) activation of some components of the innate [natural killer (NK) cells] or adoptive immune system (T cells), (b) modification of cytokine microenvironment in(More)
In Bangalore, cancer of the oesophagus is the third most common cancer in males and fourth most common in females with average annual age-adjusted incidence rates of 8.2 and 8.9 per 100,000 respectively. A case-control investigation of cancer of the oesophagus was conducted based on the Population-based cancer registry, Bangalore, India. Three hundred and(More)
The peripheral T-cell lymphomas (PTCLs) include a pathologic and clinically heterogeneous group of mature aggressive T-cell lymphomas, with overall inferior prognoses compared with aggressive B-cell lymphomas. Diagnosis by expert pathologic analysis is paramount in differentiating the multiple different clinicopathologic subtypes. The clinical presentations(More)
The peripheral T-cell lymphomas are a rare and heterogeneous group of mature T-cell lymphomas with limited available therapies. The outcome of frontline chemotherapy regimens has been disappointing, with a long-term survival of only 20%-30%. There is an urgent need to optimize induction therapy by incorporating novel agents that target the dysregulated(More)
BACKGROUND Proteasome inhibition results in antitumor activity through various mechanisms, including disruption of cell cycle progression and control, induction of apoptosis, and inhibition of proliferation. DESIGN This review assesses preclinical data on the ability of bortezomib, the first proteasome inhibitor approved for clinical use, to enhance(More)
For centuries humans have used plants as a source of food, fi ber, fuel, and medicine because they have the ability to synthesize a vast array of complex organic compounds using light, carbon dioxide, and water. Advances in recombinant DNA and transgenic technologies during the last several decades have opened many new avenues to further exploit plants for(More)
TPS138 Background: Approximately 40% patients with an intermediate/high to high-risk IPI score will relapse in the first year after completion of standard therapy with R-CHOP. Lenalidomide, an immunomodulatory drug, has activity in relapsed diffuse large B-cell lymphoma (DLBCL). Our pre-clinical data demonstrated that lenalidomide enhances the natural(More)
MYC/BCL2 double hit lymphoma (DHL) has been the subject of many studies; however, no study has systemically compared the clinicopathologic features and prognostic factors between patients with de novo disease versus those with a history of follicular lymphoma (FL). In addition, the prognostic importance of several other issues remains controversial in these(More)